Annual General Meeting of Kuros Biosciences approves all resolutions

Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. 

The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2023 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the Executive Committee, voted in favor of the proposed appropriation of the Annual Results, and approved the compensation for the members of the Board of Directors and the Executive Committee. Clemens van Blitterswijk was re-elected as Chairman and Joost de Bruijn as well as Oliver Walker were re-elected as members of the Board. Scott Bruder did not stand for re-election. Albert Arp and Chris Fair (CEO) were elected as new members of the Board of Directors. Clemens van Blitterswijk and Oliver Walker were re-elected as members of the Compensation Committee and Albert Arp was elected as a new member of the Compensation Committee. The law firm Keller AG, Zurich, was re-elected as independent Proxy. PricewaterhouseCoopers Ltd, Basel, were re-elected for another one-year term as Kuros' auditor.

The Annual General Meeting further approved, with the required 2/3 majority, adjustments to the articles of association. Adjustments included the introduction of a Capital Band and the increase of the Conditional Share Capital for Employees, Persons of Comparable Positions and Board Members.

The Annual General Meeting took place at JED Events, Zürcherstrasse 39E, 8952 Schlieren (Zurich).  22’284’902 shares or 60.4% of a total of 36,896,008 shares were represented.

For further information, please contact:

About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic fusion technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOsTM, is a unique advanced biologic that has already been used across three continents in 25,000 fusion surgeries. For more information on the company, its products and pipeline, visit kurosbio.com.

Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.